Open Access

ORIGINAL ARTICLE

IL-8 as a potential biomarker in Guillain-Barre Syndrome

Gautier Breville¹, Agustina M. Lascano¹, Pascale Roux-Lombard^2,4, Patrice H. Lalive^1,2,3

1 Department of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland
2 Department of Diagnostic Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
3 Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
4 Department of Medicine, Division of Immunology and Allergy, Geneva University Hospitals, Geneva, Switzerland

* Corresponding Author: G. Breville,

European Cytokine Network 2019, 30(4), 130-134. https://doi.org/10.1684/ecn.2019.0436

Accepted 11 November 2019;

Abstract

This pilot study was designed to compare the levels of interleukin-8 (IL-8), a pro-inflammatory chemokine, in the cerebrospinal fluid (CSF) of patients with Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), non-inflammatory polyneuropathy (PNP), and other non-inflammatory neurological diseases (functional syndrome or migraine). The results show elevated CSF IL-8 levels in GBS compared to the other groups (p < 0.05). IL-8 could be considered a potential biomarker to differentiate GBS from CIDP. This distinction could be relevant in terms of therapeutic decisions and functional prognosis.

---

Keywords

---